Skip to content

Exploring Glycemic Responses Through Continuous Monitoring in a Healthy Population

Exploring Glycemic Responses Through Continuous Monitoring in a Healthy Population

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06900439
Enrollment
1189
Registered
2025-03-28
Start date
2025-03-21
Completion date
2025-05-31
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucose Control, Gut Microbiome

Keywords

CGM, Continuous Glucose Monitor, Glucose, Gut Microbiome, Healthy Population, Glycemic Response

Brief summary

PREDICT REFINE is a sub-study of PREDICT 3 with the primary aim of exploring glycemic responses through continuous glucose monitoring in a healthy population. The study will explore glycemic responses to a standardised test meal before and after a personalised dietary programme. The sub-study will include wearing a Continuous Glucose Monitor for 14 days, collecting information around diet and health, providing a stool sample, and consuming a standardised test meal. By conducting this study researchers hope to better understand Continuous Glucose Monitoring accuracy and variability in healthy individuals, the impact of diet on glycemic responses over time, and potential mechanisms by which changes in microbiome health may influence glycemic control.

Detailed description

PREDICT REFINE is a single-arm mechanistic intervention study designed as a sub-study of PREDICT 3. The primary objective is to explore glycemic responses through continuous glucose monitoring (CGM) in a healthy population, specifically examining responses to a standardized test meal before and after a personalised dietary programme. Study Population and Recruitment: The study population consists of individuals who have previously enrolled in the commercial ZOE testing program, consented to participate in the PREDICT 3 study, and provided consent for scientific research at ZOE. Prospective participants will be selected based on predefined inclusion and exclusion criteria by the study management team. Recruitment will be conducted via email, with potential participants receiving a Participant Information Sheet. A minimum of 24 hours will be provided for individuals to consider participation. Those interested will complete an online screening form via a secure survey platform, and eligible participants will be asked to provide informed consent. Study Design and Procedures: Following informed consent, participants will undergo the following study tasks in a 14 day timeframe: 1. Continuous Glucose Monitoring: Participants will wear a CGM device for 14 days to record continuous data on blood glucose responses. 2. Data Collection: Participants will be required to provide comprehensive information about their diet and health during the study period. This will include completing food logs, a food frequency questionnaire, and a health + lifestyle questionnaire on a mobile app. 3. Biological Sample Collection: Participants will provide a stool sample, which will be analyzed using metagenomic sequencing. 4. Consume a Standardized Test Meal: Participants will consume a standardized test meal under controlled conditions. As participants will be recruited from the PREDICT 3 study, the above tasks would have been completed at baseline, \ 4 months prior to the start of the sub study while participating in PREDICT 3. Study consent will allow baseline and endpoint data (collected as part of this sub-study) to be connected.

Interventions

OTHERDietary Intervention

To carry out a dietary intervention using a standardized test meal where the participant's postprandial glucose to the meal is measured with a continuous glucose monitor and compared to the participant's postprandial glucose from the same standardized test meal 4 months prior.

Sponsors

Zoe Global Limited
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

A single-arm mechanistic intervention study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Enrolled in the ZOE product & purchased a Gut Health Retest at month 4 * Any sex * Minimum 18 years of age * Body mass index (BMI) greater than or equal to 18.5 kg/m2 * If under care for any chronic medical conditions (including type 2 diabetes), you have confirmed with your treating physician that this sub study is safe for you. This does not apply to conditions listed in the

Exclusion criteria

. * Able and willing to comply with the study protocol and provide informed consent before your ZOE Gut Health Retest is fulfilled and posted. * Live in the United Kingdom

Design outcomes

Primary

MeasureTime frameDescription
Glycaemic ControlBaseline and Month 4Measurement of glycaemic control with a continuous glucose monitor (CGM).

Secondary

MeasureTime frameDescription
Gut Microbiome CompositionBaseline and Month 4The measurement of relative abundance of microbiome species, derived from metagenomic analysis of stool samples.
Gut Microbiome DiversityBaseline and Month 4The measurement of diversity metrics (e.g. richness, evenness, ranking of species associated with diet and health) derived from metagenomic analysis of stool samples.

Other

MeasureTime frameDescription
Dietary IntakeBaseline and Month 4The measurement of habitual and acute dietary intake through a food frequency questionnaire and food logs.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026